פרבנאר 13 - Prevenar 13

×©××× ××Â !
××ª××¨××: 29/07/2025 ××ª×§××× ××××¢× ×× ×©××××§ ××ª×¨××¤× ×××¤×¡×§ ××¦×××ª××ª.

× ×ª×× × ×ª×¨××¤×

××¡× ×××¨××××ª

×××¨×©×

××× ×× ×× × ××¡×¤××

×§×××¦× ×¤×¨××§××××××ª (ATC4)

J07AL
Pneumococcal vaccines

××¨××× ×¤×¢×× (ATC5)

Pneumococcal polysaccharide serotype 1 2.2 MCG / 0.5 ML âJ07AL02
Pneumococcal polysaccharide serotype 14 2.2 MCG / 0.5 ML âJ07AL02
Pneumococcal polysaccharide serotype 18C 2.2 MCG / 0.5 ML âJ07AL02
Pneumococcal polysaccharide serotype 19 F 2.2 MCG / 0.5 ML âJ07AL02
Pneumococcal polysaccharide serotype 19A 2.2 MCG / 0.5 ML âJ07AL02
Pneumococcal polysaccharide serotype 23F 2.2 MCG / 0.5 ML âJ07AL02
Pneumococcal polysaccharide serotype 3 2.2 MCG / 0.5 ML âJ07AL02
Pneumococcal polysaccharide serotype 4 2.2 MCG / 0.5 ML âJ07AL02
Pneumococcal polysaccharide serotype 5 2.2 MCG / 0.5 ML âJ07AL02
Pneumococcal polysaccharide serotype 6A 2.2 MCG / 0.5 ML âJ07AL02
Pneumococcal polysaccharide serotype 6B 4.4 MCG / 0.5 ML âJ07AL02
Pneumococcal polysaccharide serotype 7F 2.2 MCG / 0.5 ML âJ07AL02
Pneumococcal polysaccharide serotype 9V 2.2 MCG / 0.5 ML âJ07AL02

×¦××¨×ª ××ª×

×ª×× ×©×¨××¨× - I.M

×¦××¨×ª ××× ××

×ª×¨×××£ ××××¨×§×, SUSPENSION FOR INJECTION
××× ××¢×ª ××× ×× ××ª×¨ ×× ××¨×¢×× ××© ××××× ××ª ××ª×¨××¤× ×××ª×× ×××× ×× ××××××¥ ××¤× ×©×××¤××¢ ××¢××× ××¦×¨××

××ª××××

Active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to 17 years of age.Active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in adults â¥18 years of age and the elderly

× ×ª×× × ××¡×

×ª××¨×× ××××× ××¡×

15/05/2006

××××××ª ××¡×

×ª×¨××¤× ××××××ª ××¨××©×× ×¢'× ×¨××¤× ××××× ×× ××××× ×××¨×ª

××ª×××× ××¡×

××ª××××	×ª××¨×× ×××××	×ª××× ×§××× ×	Class Effect	××¦× ××××	××¡××¡ ××××××ª

×©××××© ××¡×

Vaccination should be considered for the following high risk groups: after splenectomy or splenic dysfunction (sickle cell anaemia), nephrotic syndrome, persons with chronic illness who may be at a greater risk of pneumococcal infections

××¡××¨×ª ××××× ××¡×

××ª×¨××¤× ×ª×× ×ª× ×××××× ××× ×××× 8 ×©×××¢××ª ××¢× ×××× 59 ××××©××, ××©×¨ ××©×ª××××× ××§×××¦××ª ××¡×××× ××××:

1. ××¤×¨×¢××ª ××¤×¢××××ª ××××× (×× ××××××ª ×× ×ª×¤×§×××××ª), ×××× ××¨××ª×ª ××××, ×××¡×¨ ×××× ××××, ×× ××× ××¨××©××ª (SCD) ××××××.

2. ×××§×××× ××××× ××××××× ×¢×§×:

×. ×××××ª ×××××¨××ª, ×××× ×××§××× ×××××¤×××.

×. ×××¤×× ×××× ××¡×× ××ª (×××× ××§×¨× ××ª, ××××¨×× ×¦××××××§×¡×××).

×. ××××× HIV.

5. ×× ×¡×¤××§×ª ×××××ª ××¨×× ××ª, ×ª×¡××× ×ª × ×¤×¨××××ª, ×××¤×× ××××××××.

6. ×××× Ataxia Telangiectasia.

×¢××× ××¨××¤× ×××××¨××ª ××¢×××

×¢××× ××¨××¤× 13.01.2021

××××¨× ××¢××× 13.01.2021
××××¨× ××¢××× 25.03.2020
××××¨× ××¢××× ××¨××¤× 15.07.2018
××××¨× ××¢××× ××¨××¤× 21.06.2015 (××¡×× Microsoft Word)
××××¨× ××¢××× ××¨××¤× 31.12.2013 (××¡×× Microsoft Word)
××××¨× ××¢××× 13.08.2013 (××¡×× Microsoft Word)
××××¨× ××¢××× 19.12.2012 (××¡×× Microsoft Word)
××××¨× ××¢××× 29.11.2011 (××¡×× Microsoft Word)

×¢××× ××¦×¨××	Â ×¢××× ××¦×¨×× ×¢××¨××ª 13.01.2021 ×¢××× ××¦×¨×× ×× ××××ª - Patient information leaflet â13.01.2021 ×¢××× ××¦×¨×× ×¢×¨×××ª - ÙØ´Ø±Ø© ÙÙÙØ³ØªÙÙÙ Ø¨Ø§ÙÙØºØ© Ø§ÙØ¹Ø±Ø¨ÙØ© 13.01.2021

×¢×¨××× ×××××§××¨×¤×××	×¢×¨××× ×§×©××¨×× ×××××§××¨×¤×××
×¤×¨×× ××¨ 13 ×××××¨ ××©×¨× ×××¨××××ª

×××¤××© ××××¨××	××××¨×× ×-PubMed
××××¢ ××¨×©×ª	RxList WebMD Drugs.com
×©× ××¦×¨×	JOHN WYETH AND BROTHER LIMITED; TRADING AS WYETH PHARMACEUTICALS, UK
×©× ××¢× ××¨××©××	PFIZER PHARMACEUTICALS ISRAEL LTD
×¨××©×××	×ª××¨×× ×××©×: 10/2009. ×¨××©××× ××ª××¨××: 05/2015
×ª××¨×× ×¢×××× ×××¨××	29/07/2025

×ª××× ×ª ××¨×××

×ª××× ×ª ××¨×××

השינוי האחרון נעשה בֹ־9 במרץ 2024 ב־17:42

פרבנאר 13 - Prevenar 13

ויקיתרופות